CN101351476B - 抗体可变区的糖基化 - Google Patents

抗体可变区的糖基化 Download PDF

Info

Publication number
CN101351476B
CN101351476B CN2006800463079A CN200680046307A CN101351476B CN 101351476 B CN101351476 B CN 101351476B CN 2006800463079 A CN2006800463079 A CN 2006800463079A CN 200680046307 A CN200680046307 A CN 200680046307A CN 101351476 B CN101351476 B CN 101351476B
Authority
CN
China
Prior art keywords
antibody
disease
composition
glycosylated
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800463079A
Other languages
English (en)
Chinese (zh)
Other versions
CN101351476A (zh
Inventor
H·洛茨西尔
W·赫伯
D·舒鲍尔
K·魏尔
M·布洛克豪斯
B·宝曼
H·科尔
A·绍布玛
K·兰奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to CN201210137369.8A priority Critical patent/CN102659943B/zh
Publication of CN101351476A publication Critical patent/CN101351476A/zh
Application granted granted Critical
Publication of CN101351476B publication Critical patent/CN101351476B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
CN2006800463079A 2005-12-12 2006-12-11 抗体可变区的糖基化 Active CN101351476B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210137369.8A CN102659943B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05027090.9 2005-12-12
EP05027090 2005-12-12
PCT/EP2006/011914 WO2007068429A1 (en) 2005-12-12 2006-12-11 Antibodies against amyloid beta 4 with glycosylated in the variable region

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210137369.8A Division CN102659943B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Publications (2)

Publication Number Publication Date
CN101351476A CN101351476A (zh) 2009-01-21
CN101351476B true CN101351476B (zh) 2013-04-03

Family

ID=37745986

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2006800463079A Active CN101351476B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化
CN201210137369.8A Active CN102659943B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210137369.8A Active CN102659943B (zh) 2005-12-12 2006-12-11 抗体可变区的糖基化

Country Status (33)

Country Link
US (2) US8906370B2 (enExample)
EP (2) EP2377886A1 (enExample)
JP (1) JP5145241B2 (enExample)
KR (2) KR101401159B1 (enExample)
CN (2) CN101351476B (enExample)
AR (1) AR057233A1 (enExample)
AT (1) ATE517923T1 (enExample)
AU (1) AU2006326301B2 (enExample)
BR (1) BRPI0619605B8 (enExample)
CA (1) CA2632828C (enExample)
CR (1) CR10000A (enExample)
CY (1) CY1114783T1 (enExample)
DK (1) DK1960428T3 (enExample)
DO (1) DOP2006000278A (enExample)
EC (1) ECSP088524A (enExample)
ES (1) ES2368591T3 (enExample)
IL (1) IL191004A (enExample)
JO (1) JO2824B1 (enExample)
MA (1) MA30038B1 (enExample)
MY (1) MY155286A (enExample)
NO (1) NO346105B1 (enExample)
NZ (1) NZ568241A (enExample)
PE (3) PE20100684A1 (enExample)
PL (1) PL1960428T3 (enExample)
PT (1) PT1960428E (enExample)
RS (1) RS52004B (enExample)
RU (1) RU2438706C2 (enExample)
SI (1) SI1960428T1 (enExample)
TW (1) TWI382990B (enExample)
UA (1) UA99097C2 (enExample)
UY (1) UY30003A1 (enExample)
WO (1) WO2007068429A1 (enExample)
ZA (1) ZA200805038B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659943A (zh) * 2005-12-12 2012-09-12 豪夫迈·罗氏有限公司 抗体可变区的糖基化

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
RU2522481C2 (ru) 2007-06-29 2014-07-20 Ф.Хоффманн-Ля Рош Аг Мутант тяжелой цепи, приводящий к повышенной выработке иммуноглобулина
DK3216802T3 (da) 2007-08-20 2021-01-04 Glaxo Group Ltd Produktionsfremgangsmåde
ES2445590T3 (es) 2007-10-05 2014-03-04 Genentech, Inc. Uso de anticuerpo anti-amiloide beta en enfermedades oculares
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
CA2975228C (en) * 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2010127069A1 (en) * 2009-04-29 2010-11-04 Schering Corporation Antibody purification
US20130116413A1 (en) * 2009-12-29 2013-05-09 Dr. Reddy's Laboratories, Inc. Purification of proteins
EA201201227A1 (ru) 2010-03-03 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Бипаратопные а-бета-связывающие полипептиды
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
IN2014CN03555A (enExample) * 2011-10-25 2015-07-03 Onclave Therapeutics Ltd
CN103998930A (zh) * 2011-12-02 2014-08-20 普拉希京公司 用于形成和检测斑块的斑块阵列方法和组合物
SI2822587T1 (sl) 2012-03-08 2016-04-29 F. Hoffmann-La Roche Ag Farmacevtska oblika abeta protitelesa
PT2890712T (pt) * 2012-08-29 2019-06-28 Hoffmann La Roche Transportador para a barreira hematoencefálica
CN102998454A (zh) * 2012-12-11 2013-03-27 华中师范大学 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法
WO2014100139A1 (en) 2012-12-18 2014-06-26 The Rockefeller University Glycan-modified anti-cd4 antibodies for hiv prevention and therapy
US9587022B2 (en) 2012-12-18 2017-03-07 The Rockefeller University Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity
EP3594230A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
JP6169885B2 (ja) 2013-05-07 2017-07-26 株式会社日立製作所 精製装置及び精製方法
IL244149B2 (en) 2013-09-13 2025-09-01 Genentech Inc Methods and compositions containing purified recombinant polypeptides
CA3174012A1 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
EP3072506B1 (en) 2013-11-22 2022-04-20 The University of Tokyo Carrier for drug delivery and conjugate, composition containing same, and method for administering same
WO2015155694A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
AU2016312909B2 (en) 2015-08-21 2022-12-08 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
EP3155958B1 (en) * 2015-10-16 2021-11-17 Roche Diabetes Care GmbH A method for operating a system and a system
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
HK1259324A1 (zh) 2015-11-09 2019-11-29 英属哥伦比亚大学 淀粉样蛋白β表位及其抗体
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
US10792477B2 (en) * 2016-02-08 2020-10-06 Orbusneich Medical Pte. Ltd. Drug eluting balloon
WO2017153848A1 (en) * 2016-03-10 2017-09-14 Genomic Vision Method of curvilinear signal detection and analysis and associated platform
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
EP3632421B1 (en) * 2017-05-30 2025-08-13 Morinaga Milk Industry Co., Ltd. Acetic acid and/or an acetic acid salt for use in the treatment of alzheimer-type dementia
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
WO2019014768A1 (en) 2017-07-18 2019-01-24 The University Of British Columbia ANTI-BETA-AMYLOID ANTIBODY
CN108048477A (zh) * 2017-12-15 2018-05-18 南京理工大学 基于大肠杆菌表达系统的制备多肽的方法
EP3778875A1 (en) 2019-08-14 2021-02-17 MaxiVax SA Immortalized myoblast cell lines and uses thereof
WO2022020680A1 (en) 2020-07-23 2022-01-27 Othair Prothena Limited Anti-abeta antibodies
KR20230109674A (ko) 2020-11-16 2023-07-20 에프. 호프만-라 로슈 아게 Fab 고 만노스 당형
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591429B (zh) * 2022-05-07 2022-08-09 北京第一生物化学药业有限公司 结合β-淀粉样蛋白的抗体及其用途
TW202434629A (zh) 2023-01-26 2024-09-01 愛爾蘭商歐薩爾普羅席納有限公司 以抗類澱粉β (ABETA)抗體治療神經病症之方法
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
CN117783359B (zh) * 2023-12-28 2024-12-31 中国计量科学研究院 一种基于串联质谱的转基因蛋白多靶同检方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
CA1339014C (en) 1987-10-08 1997-03-25 Ronald E. Majocha Antibodies to a4 amyloid peptide
JP2780507B2 (ja) 1991-03-29 1998-07-30 松下電器産業株式会社 内燃機関用フィルタ再生装置
WO1994017197A1 (fr) 1993-01-25 1994-08-04 Takeda Chemical Industries, Ltd. ANTICORPS DIRIGE CONTRE LE β-AMYLOIDE OU UN DERIVE DE CE DERNIER ET SON UTILISATION
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
GB9416007D0 (en) * 1994-08-08 1994-09-28 Erba Carlo Spa Anthracyclinone derivatives
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
EP0838033A1 (en) * 1995-06-06 1998-04-29 Stemcell Therapeutics L.L.C. GLYCOPROTEIN gp105 ON BL3 HEMATOPOIETIC STEM CELLS
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
BR0008738A (pt) * 1999-03-04 2001-12-26 Praecis Pharm Inc Moduladores de agregação de peptìdeobeta-amilóide compreendendo d-aminoácidos
WO2000077178A1 (en) 1999-06-16 2000-12-21 Boston Biomedical Research Institute IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
WO2001015655A2 (en) 1999-08-31 2001-03-08 Ramot University Authority For Applied Research & Industrial Development Ltd. Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
KR20080059676A (ko) 1999-11-29 2008-06-30 뉴로겜 인터내셔널 리미티드 알츠하이머 및 아밀로이드 관련 질병의 예방 및 치료용백신
EP1125905A1 (en) 2000-02-16 2001-08-22 Pepscan Systems B.V. Segment synthesis
SI1257584T2 (sl) 2000-02-24 2013-07-31 Washington University St. Louis Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
CA2313828A1 (en) 2000-08-01 2002-02-01 Institut De Recherches Cliniques De Montreal/Ircm Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CA2436789A1 (en) 2000-12-19 2002-08-22 Palatin Technologies, Inc. Identification of target-specific folding sites in peptides and proteins
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
AU2002257162A1 (en) 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
US20040192898A1 (en) * 2001-08-17 2004-09-30 Jia Audrey Yunhua Anti-abeta antibodies
PT1944040E (pt) * 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR0315157A (pt) 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AR057233A1 (es) * 2005-12-12 2007-11-21 Hoffmann La Roche Glicosilacion en la region variable
TW200831133A (en) * 2006-12-11 2008-08-01 Hoffmann La Roche Mab Abeta lyophylized formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659943A (zh) * 2005-12-12 2012-09-12 豪夫迈·罗氏有限公司 抗体可变区的糖基化
CN102659943B (zh) * 2005-12-12 2015-07-01 豪夫迈·罗氏有限公司 抗体可变区的糖基化

Also Published As

Publication number Publication date
PT1960428E (pt) 2011-10-07
BRPI0619605A8 (pt) 2019-01-15
CA2632828A1 (en) 2007-06-21
UY30003A1 (es) 2007-08-31
BRPI0619605B8 (pt) 2021-05-25
ECSP088524A (es) 2008-07-30
US9272031B2 (en) 2016-03-01
CR10000A (es) 2008-07-29
PE20100748A1 (es) 2010-11-12
HK1130066A1 (en) 2009-12-18
TW200736273A (en) 2007-10-01
NZ568241A (en) 2011-08-26
MY155286A (en) 2015-09-30
JP5145241B2 (ja) 2013-02-13
CN102659943A (zh) 2012-09-12
PE20100684A1 (es) 2010-10-04
NO346105B1 (no) 2022-02-21
UA99097C2 (ru) 2012-07-25
PE20071002A1 (es) 2007-11-19
EP1960428A1 (en) 2008-08-27
EP2377886A1 (en) 2011-10-19
KR101401159B1 (ko) 2014-05-29
US20150165022A1 (en) 2015-06-18
CN101351476A (zh) 2009-01-21
RU2438706C2 (ru) 2012-01-10
AU2006326301B2 (en) 2011-04-21
DOP2006000278A (es) 2007-07-15
JP2009520691A (ja) 2009-05-28
SI1960428T1 (sl) 2011-10-28
KR20120089483A (ko) 2012-08-10
JO2824B1 (en) 2014-09-15
BRPI0619605B1 (pt) 2019-08-13
AU2006326301A1 (en) 2007-06-21
US8906370B2 (en) 2014-12-09
HK1176075A1 (en) 2013-07-19
CN102659943B (zh) 2015-07-01
DK1960428T3 (da) 2011-08-22
ZA200805038B (en) 2009-06-24
ES2368591T3 (es) 2011-11-18
RS52004B (sr) 2012-04-30
MA30038B1 (fr) 2008-12-01
CY1114783T1 (el) 2016-12-14
TWI382990B (zh) 2013-01-21
CA2632828C (en) 2012-07-10
NO20082874L (no) 2008-08-28
AR057233A1 (es) 2007-11-21
EP1960428B1 (en) 2011-07-27
RU2008128138A (ru) 2010-01-20
US20090252724A1 (en) 2009-10-08
KR20080077132A (ko) 2008-08-21
BRPI0619605A2 (pt) 2011-10-11
ATE517923T1 (de) 2011-08-15
PL1960428T3 (pl) 2012-02-29
IL191004A (en) 2013-08-29
WO2007068429A1 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
CN101351476B (zh) 抗体可变区的糖基化
RU2725958C2 (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
AU2014204465B2 (en) Humanized antibodies to amyloid beta
TWI355389B (en) Antibodies directed against amyloid-beta peptide a
US8444970B2 (en) Compositions and methods for treating ocular diseases and conditions
SG173385A1 (en) Humanized antibody against amyloid beta
HK1130066B (en) Antibody glycosylation in the variable region
AU2018204837A1 (en) Humanized antibody against amyloid beta
MX2008006948A (es) Glicosilacion en la region variable
HK1242343B (zh) 用於抑制masp-2依赖的补体活化的组合物
HK1176075B (en) Antibody glycosylation in the variable region
HK1140433B (en) Humanized antibodies to amyloid beta
HK1183631A (en) Humanized antibodies to amyloid beta

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1130066

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1130066

Country of ref document: HK